Abstract
Due to multi-faceted pathology of AD; no drug can seize the progress of the disease, whereas only the symptomatic treatment is available at the moment. Several drug classes to treat AD are available in clinical use, AChEIs being the most prescribed. In addition to AChEIs, secretase enzymes and iron chelators have turned out to be the focus of research and the popular targets in drug discovery against AD. The latest approaches such as immunotherapy, multi-targeted drug ligand design, AChE inhibitors, antioxidants, metal chelators, monoamine oxidase (MAO) inhibitors, antiinflammatory drugs, and N-methyl-D-aspartate (NMDA) inhibitors are currently in use to cure this disease to some extent. But, there is a certain need to develop new drugs to fight with AD, particularly acting on multi-targets or with dual mechanisms of action. In this review, a particular emphasis will be focused on multitargets aiming at AD to design new drug molecules with respect to treatment strategies and preventive measures. Since the underlying pathogenesis of AD is complicated and still under investigation, the attempts to design highly selective and potent agents to treat AD are quite intensively continuing. In this respect, designing novel drugs with dual/multi-acting mechanisms seems to be more rational.
Keywords: Alzheimer’s disease, Neurodegeneration, Drug design, Cholinesterase, Secretase, Multi-target, Monoamine oxidase, Iron chelation.
Current Topics in Medicinal Chemistry
Title:Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Volume: 16 Issue: 17
Author(s): Ilkay Erdogan Orhan and F. Sezer Senol
Affiliation:
Keywords: Alzheimer’s disease, Neurodegeneration, Drug design, Cholinesterase, Secretase, Multi-target, Monoamine oxidase, Iron chelation.
Abstract: Due to multi-faceted pathology of AD; no drug can seize the progress of the disease, whereas only the symptomatic treatment is available at the moment. Several drug classes to treat AD are available in clinical use, AChEIs being the most prescribed. In addition to AChEIs, secretase enzymes and iron chelators have turned out to be the focus of research and the popular targets in drug discovery against AD. The latest approaches such as immunotherapy, multi-targeted drug ligand design, AChE inhibitors, antioxidants, metal chelators, monoamine oxidase (MAO) inhibitors, antiinflammatory drugs, and N-methyl-D-aspartate (NMDA) inhibitors are currently in use to cure this disease to some extent. But, there is a certain need to develop new drugs to fight with AD, particularly acting on multi-targets or with dual mechanisms of action. In this review, a particular emphasis will be focused on multitargets aiming at AD to design new drug molecules with respect to treatment strategies and preventive measures. Since the underlying pathogenesis of AD is complicated and still under investigation, the attempts to design highly selective and potent agents to treat AD are quite intensively continuing. In this respect, designing novel drugs with dual/multi-acting mechanisms seems to be more rational.
Export Options
About this article
Cite this article as:
Erdogan Orhan Ilkay and Sezer Senol F., Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease, Current Topics in Medicinal Chemistry 2016; 16 (17) . https://dx.doi.org/10.2174/1568026616666160204121832
DOI https://dx.doi.org/10.2174/1568026616666160204121832 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction and Alzheimers Disease
Current Alzheimer Research A Protective Role of Translocator Protein in Alzheimer’s Disease Brain
Current Alzheimer Research Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Gender and Pathology-Specific Effect of Apolipoprotein E Genotype on Psychosis in Alzheimer’s Disease
Current Alzheimer Research Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges
Current Medicinal Chemistry Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design A Predictive Model of the Prevalence of Delirium in Elderly Subjects Admitted to Nursing Homes
Endocrine, Metabolic & Immune Disorders - Drug Targets Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemical and Molecular Aspects on Interactions of Galanthamine and Its Derivatives with Cholinesterases
Current Pharmaceutical Biotechnology Striving for a Fuller Characterization of the Cellular Neuropathology of Depression Subtypes
Current Psychiatry Reviews Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Relations between Sensorimotor Integration and Speech Disorders in Parkinson's Disease
Current Alzheimer Research Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy Different Effect of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub> on Amyloid-β40 Aggregation In Vitro
Current Alzheimer Research Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Issues of Quantitative Metabolic Brain Imaging with Small Animal PET in Mice
Current Medical Imaging